A chance at relief isn’t luck.
It’s ILARIS.
The only FDA-approved treatment for active Still’s disease, including Adult-Onset Still’s Disease (AOSD) and Systemic Juvenile Idiopathic Arthritis (SJIA) in patients 2 years of age and older.1
Not an actual patient. Individual results will vary.
See how to identify Still’s disease and what it looks like
In clinical trials, ILARIS was proven to help manage symptoms in patients with Still’s disease1
Safety profile of ILARIS in patients aged 2 years and older1
ILARIS is the only FDA-approved once-monthly treatment in Still’s disease1
Access and Support
ILARIS Companion
View information about the patient support program and how to enroll in these services.
Downloadable Resources
Find access information about ILARIS as well as helpful resources for both HCPs and patients.
IL, interleukin; MOA, mechanism of action; MOD, mechanism of disease.
References: 1. Ilaris. Prescribing information. Novartis Pharmaceuticals Corp. 2. Lachmann HJ, Quartier P, So A, Hawkins PN. The emerging role of interleukin-1β in autoinflammatory diseases. Arthritis Rheum. 2011;63(2):314-324. doi:10.1002/art.30105 3. Macovei LA, Burlui A, Bratoiu I, et al. Adult-onset Still’s disease—a complex disease, a challenging treatment. Int J Mol Sci. 2022;23(21):12810. doi:10.3390/ijms232112810 4. Lopalco G, Cantarini L, Vitale A, et al. Interleukin-1 as a common denominator from autoinflammatory to autoimmune disorders: premises, perils, and perspectives. Mediators Inflamm. 2015;2015:194864. doi:10.1155/2015/194864